Pfizer To Pay $486M To Settle Celebrex, Bextra Securities MDL
Law360, New York (August 2, 2016, 12:18 PM EDT) -- Pfizer Inc. will pay $486 million to settle long-running multidistrict litigation accusing it of misleading investors about the alleged risks of its pain treatments Celebrex and Bextra, according to an earnings report the pharmaceutical company filed Tuesday.
Pfizer will pay $486 million to end litigation, first filed in 2004, alleging the drugmaker and its top executives repeatedly misled investors regarding the safety of Celebrex and Bextra, which are primarily used to treat arthritis pain. (Credit: AP) Financial tables Pfizer filed with the U.S. Securities and Exchange Commission on Tuesday included expenses for a $486 million deal to end litigation first filed in...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!